Key Highlights

  • Two priority review vouchers are being sold for a combined USD 413 million, and Ultragenyx (NASDAQ:RARE) expects roughly USD 350 million on a net basis once the second sale closes.
  • Headcount falls by about 20% to around 1,000 people, with 2027 Research and Development spending targeted below USD 350 million and selling, general and administrative costs below USD 375 million.
  • Revenue for the third quarter of 2026 reached USD 173 million, versus USD 160 million a year earlier, while the loss shrank to USD 118 million compared with USD 180 million before.
  • Cash, cash equivalents and marketable securities totaled USD 401 million on September 30, 2026, a figure that excludes the voucher proceeds.

Two Approvals Unlock Vouchers Worth USD 413 Million

Ultragenyx (NASDAQ:RARE) develops treatments for rare and ultra-rare genetic disorders, and it released third quarter results on November 3, 2026, covering the period ended September 30. Two regulatory wins generated the vouchers: in August the FDA allowed Genglycos onto the market under Accelerated Approval for glycogen storage disease type Ia, and in September Fayuvi received full approval for Sanfilippo syndrome type A. Each approval came with a priority review voucher, a tradable credential that speeds up review of a future application. The Genglycos transaction, at USD 210 million, is complete. The Fayuvi agreement, at USD 203 million, is set to close later in November, and together the two lift proceeds to USD 413 million, or roughly USD 350 million after netting.

Revenue Edges Up as Spending Is Cut Sharply

Top-line sales came in at USD 173 million, against USD 160 million the prior year. Crysvita produced USD 109 million, Dojolvi USD 30 million, Evkeeza USD 24 million and Mepsevii USD 10 million. For 2026 the company kept its Revenue range at USD 730 million to USD 760 million, leaving launch sales out of that figure. Spending on research and development dropped to USD 154 million, down from USD 216 million, whereas the SG&A line widened to USD 97 million, up from USD 87 million. The restructuring winds down the GTX-102 Angelman studies, ends UX701 for Wilson disease after it missed study goals, and reduces real estate. Roughly USD 25 million of charges are expected in the fourth quarter.

Profit Target for 2027 Hinges on Launches and Cost Cuts

The company still aims for full-year GAAP profitability in 2027. That goal rests on the two gene therapy launches, which are its first gene therapy treatments, on organic growth in the existing portfolio and on delivering the savings. Downside scenarios include an FDA Withdrawal of Genglycos accelerated approval if confirmatory trials Fail to show benefit, a delayed Fayuvi sale, reliance on Kyowa Kirin for Crysvita in some markets, and execution strain from Job cuts. DTX301 Phase 3 readouts in ornithine transcarbamylase deficiency are due during the first half of 2027, while dialogue with regulators about UX143 in osteogenesis imperfecta is still open. The call started at 5 p.m. ET on November 3, 2026.

Where Things Stand

Ultragenyx (NASDAQ:RARE) can reach 2027 profitability, but the vouchers alone will not decide it, so the honest answer is that it depends on execution. The USD 413 million and USD 401 million of cash give room to work with, yet the nine-month net loss reached USD 395 million, which means the Burn Rate is high. Revenue is growing modestly and the approvals are real, while two program setbacks help explain the cuts. The next checkpoints are the Fayuvi sale closing, fourth quarter launch revenue and the DTX301 readout.